Cochlear (ASX:COH) - Cotización, noticias y análisis

Resumen de acción COH

Cochlear Limited ofrece soluciones auditivas implantables para niños y adultos de todo el mundo.

COH fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	5/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 12.16%

Los beneficios aumentaron un 34% el pasado año

Análisis de riesgos

No se han detectado riesgos en COH a partir de nuestros controles de riesgos.

Competidores de Cochlear Limited

Ramsay Health Care

ASX:RHC

AU$12.0b

Sonic Healthcare

ASX:SHL

AU$12.9b

Pro Medicus

ASX:PME

AU$11.6b

Austco Healthcare

ASX:AHC

AU$58.1m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Cochlear
Historical stock prices
Current Share Price	AU$317.17
52 Week High	AU$350.17
52 Week Low	AU$220.40
Beta	0.45
1 Month Change	-6.03%
3 Month Change	4.03%
1 Year Change	29.75%
3 Year Change	43.21%
5 Year Change	65.18%
Change since IPO	10,651.53%

Noticias y actualizaciones recientes

Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively

Mar 27

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

Feb 21

Recent updates

Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value

Oct 04

Cochlear (ASX:COH) Could Be Struggling To Allocate Capital

Sep 12

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Jun 05

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

Apr 05

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Mar 04

Is Cochlear (ASX:COH) A Risky Investment?

Dec 19

Is Cochlear Limited (ASX:COH) Worth AU$205 Based On Its Intrinsic Value?

Nov 16

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Oct 25

Should Shareholders Reconsider Cochlear Limited's (ASX:COH) CEO Compensation Package?

Oct 11

Cochlear's (ASX:COH) Upcoming Dividend Will Be Larger Than Last Year's

Aug 28

Here's Why Cochlear (ASX:COH) Can Manage Its Debt Responsibly

Aug 23

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Jul 16

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

May 19

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Apr 09

Estimating The Intrinsic Value Of Cochlear Limited (ASX:COH)

Feb 04

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Dec 24

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

Oct 30

This Is Why We Think Cochlear Limited's (ASX:COH) CEO Might Get A Pay Rise Approved By Shareholders

Oct 12

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

Oct 06

Returns On Capital Signal Tricky Times Ahead For Cochlear (ASX:COH)

Aug 16

Cochlear (ASX:COH) Has A Pretty Healthy Balance Sheet

Jun 24

A Look At The Intrinsic Value Of Cochlear Limited (ASX:COH)

May 17

There Are Reasons To Feel Uneasy About Cochlear's (ASX:COH) Returns On Capital

Apr 29

These 4 Measures Indicate That Cochlear (ASX:COH) Is Using Debt Reasonably Well

Mar 20

Insider Buying: The Cochlear Limited (ASX:COH) Independent Non-Executive Director Just Bought 24% More Shares

Mar 02

Cochlear Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 20

Calculating The Intrinsic Value Of Cochlear Limited (ASX:COH)

Feb 11

Our Take On The Returns On Capital At Cochlear (ASX:COH)

Jan 25

Do Institutions Own Cochlear Limited (ASX:COH) Shares?

Jan 07

Introducing Cochlear (ASX:COH), The Stock That Zoomed 107% In The Last Five Years

Dec 21

How Much Is Cochlear Limited (ASX:COH) CEO Getting Paid?

Dec 06

Does Cochlear (ASX:COH) Have A Healthy Balance Sheet?

Nov 18

Rentabilidad de los accionistas

	COH	AU Medical Equipment	Mercado AU
7D	-0.9%	0.3%	-0.3%
1Y	29.8%	16.6%	6.1%

Rentabilidad vs. Industria: COH superó al sector Australian Medical Equipment , que obtuvo un rendimiento del 14.7% el año pasado.

Rentabilidad vs. Mercado: COH superó al mercado Australian, que obtuvo un rendimiento del 5.6% el año pasado.

Volatilidad de los precios

Is COH's price volatile compared to industry and market?
COH volatility
COH Average Weekly Movement	4.0%
Medical Equipment Industry Average Movement	10.0%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.7%
10% least volatile stocks in AU Market	3.5%

Precio estable de las acciones: COH no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de COH (4%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1981	4,800	Dig Howitt	www.cochlear.com

Cochlear Limited proporciona soluciones auditivas implantables para niños y adultos de todo el mundo. Ofrece sistemas de implante coclear, actualizaciones de procesadores de sonido, sistemas de conducción ósea, accesorios y otros productos. Cochlear Limited se fundó en 1981 y tiene su sede en Sídney (Australia).

Resumen de fundamentos de Cochlear Limited

¿Cómo se comparan los beneficios e ingresos de Cochlear con su capitalización de mercado?
Estadísticas fundamentales de COH
Capitalización bursátil	AU$21.29b
Beneficios(TTM)	AU$350.40m
Ingresos (TTM)	AU$2.15b

59.3x

Ratio precio-beneficio (PE)

9.7x

Ratio precio-ventas (PS)

¿Está COH sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de COH
Ingresos	AU$2.15b
Coste de los ingresos	AU$546.90m
Beneficio bruto	AU$1.60b
Otros gastos	AU$1.25b
Beneficios	AU$350.40m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

Aug 15, 2024

Beneficios por acción (BPA)	5.35
Margen bruto	74.56%
Margen de beneficio neto	16.30%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado COH a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

1.3%

Rentabilidad actual por dividendo

70%

Ratio de pagos

Resumen de acción COH

Recompensas

Análisis de riesgos

Competidores de Cochlear Limited

ASX:RHC

AU$12.0b

ASX:SHL

AU$12.9b

ASX:PME

AU$11.6b

ASX:AHC

AU$58.1m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Cochlear Limited Announces Company Secretary Changes

Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old

Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively

Upcoming dividend of AU$2.00 per share

First half dividend increased to AU$2.00

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

Recent updates

Cochlear Limited Announces Company Secretary Changes

Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old

Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively

Upcoming dividend of AU$2.00 per share

First half dividend increased to AU$2.00

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

First half 2024 earnings: EPS in line with expectations, revenues disappoint

Price target increased by 7.0% to AU$272

Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively

Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value

Cochlear (ASX:COH) Could Be Struggling To Allocate Capital

Upcoming dividend of AU$1.75 per share at 1.2% yield

Cochlear Limited Introduces Next Generation Cochlear Osia System with Ability to Have MRI at 3.0 T

Cochlear Limited to Report Fiscal Year 2024 Results on Aug 15, 2024

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Cochlear Limited Announces Andrew Denver, Non-Executive Director Intention to Retire At AGM to Be Held on 17 October 2023

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

Upcoming dividend of AU$1.55 per share at 1.3% yield

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

Cochlear Limited Provides Earnings Outlook for the Year 2023

Cochlear Limited (ASX:COH) announces an Equity Buyback for AUD 75 million worth of its shares.

Is Cochlear (ASX:COH) A Risky Investment?

Cochlear Limited, Annual General Meeting, Oct 17, 2023

Is Cochlear Limited (ASX:COH) Worth AU$205 Based On Its Intrinsic Value?

FDA Approves Cochlear Limited's Nucleus 8 Sound Processor, Smaller, Smarter, Better Connected Cochlear Implant Technology

Key Executive recently bought AU$97k worth of stock

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Should Shareholders Reconsider Cochlear Limited's (ASX:COH) CEO Compensation Package?

Upcoming dividend of AU$1.45 per share

Cochlear's (ASX:COH) Upcoming Dividend Will Be Larger Than Last Year's

Here's Why Cochlear (ASX:COH) Can Manage Its Debt Responsibly

Full year 2022 earnings: EPS misses analyst expectations

Cochlear Announces Final Dividend Payable on 17 October 2022

The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence

Cochlear Limited Appoints Karen Penrose to Board, Effective on 1 July 2022

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

Cochlear Limited, Annual General Meeting, Oct 18, 2022

Cochlear Limited to Report First Half, 2023 Results on Feb 15, 2023

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Upcoming dividend of AU$1.55 per share

Investor sentiment improved over the past week

First half 2022 earnings: EPS and revenues exceed analyst expectations

Cochlear Limited Announces Interim Dividend Expected to Be Payable on 21 April 2022

Estimating The Intrinsic Value Of Cochlear Limited (ASX:COH)

FDA Approves Cochlear Nucleus Implants for Unilateral Hearing Loss/Single-Sided Deafness

Capital Allocation Trends At Cochlear (ASX:COH) Aren't Ideal

Independent Non-Executive Director recently bought AU$56k worth of stock

Cochlear (ASX:COH) Seems To Use Debt Quite Sensibly

This Is Why We Think Cochlear Limited's (ASX:COH) CEO Might Get A Pay Rise Approved By Shareholders

A Look At The Fair Value Of Cochlear Limited (ASX:COH)

Cochlear Limited Advises of US Patent Infringement Complaint

Upcoming dividend of AU$1.40 per share

CEO, MD exercised options and sold AU$295k worth of stock

Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination with Cochlear Implantation

Independent Non-Executive Director recently bought AU$94k worth of stock

Independent Chairman Roderic Holliday-Smith has left the company

Independent Chairman Roderic Holliday-Smith has left the company

Full year 2021 earnings released: EPS AU$4.97 (vs AU$4.00 loss in FY 2020)